Contrasting clinical manifestations of SDHB and VHL associated chromaffin tumours.
暂无分享,去创建一个
D. Berney | U. Srirangalingam | R. Reznek | S. Chew | N. Avril | W. Drake | B. Khoo | S. Akker | A. Grossman | J. Burrin | E. Maher | N. Plowman | L. Walker | P. Pollard | E. George | Patrick J. Pollard | F. Macdonald | D. Spooner | J. Monson | R. Skelly | V. K. A. Kumar | L. Johnston | V. K. A. Kumar | V. K. A. Kumar | V. K. A. Kumar | L. B. Johnston | Shern L. Chew | V. K. A. Kumar
[1] C. Ricketts,et al. Germline SDHB mutations and familial renal cell carcinoma. , 2008, Journal of the National Cancer Institute.
[2] D. Berney,et al. Clinical manifestations of familial paraganglioma and phaeochromocytomas in succinate dehydrogenase B (SDH‐B) gene mutation carriers , 2008, Clinical endocrinology.
[3] J. Bertherat,et al. Mutations associated with succinate dehydrogenase d‐related malignant paragangliomas , 2008, Clinical endocrinology.
[4] K. Pacak,et al. Clinical presentations, biochemical phenotypes, and genotype-phenotype correlations in patients with succinate dehydrogenase subunit B-associated pheochromocytomas and paragangliomas. , 2007, The Journal of clinical endocrinology and metabolism.
[5] E. Maher,et al. Genotype–phenotype correlations in von Hippel‐Lindau disease , 2004, Human mutation.
[6] G. Stamp,et al. Expression of HIF-1α, HIF-2α (EPAS1), and Their Target Genes in Paraganglioma and Pheochromocytoma with VHL and SDH Mutations , 2006 .
[7] K. Byth,et al. Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes. , 2006, The Journal of clinical endocrinology and metabolism.
[8] G. Stamp,et al. Expression of HIF-1alpha, HIF-2alpha (EPAS1), and their target genes in paraganglioma and pheochromocytoma with VHL and SDH mutations. , 2006, The Journal of clinical endocrinology and metabolism.
[9] S. Richard,et al. Genetic testing in pheochromocytoma or functional paraganglioma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] W. Kaelin,et al. Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer. , 2005, Cancer cell.
[11] David G. Watson,et al. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. , 2005, Cancer cell.
[12] Eyal Gottlieb,et al. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. , 2005, Cancer cell.
[13] W. Kaelin. The Von Hippel-Lindau Tumor Suppressor Gene and Kidney Cancer , 2004, Clinical Cancer Research.
[14] C. Eng,et al. Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. , 2004, JAMA.
[15] A. Grossman,et al. Familial paraganglioma: a novel presentation of a case and response to therapy with radiolabelled MIBG. , 2004, Hormones.
[16] L. Aaltonen,et al. Early-onset renal cell carcinoma as a novel extraparaganglial component of SDHB-associated heritable paraganglioma. , 2004, American journal of human genetics.
[17] D. Evans,et al. Genetic analysis of mitochondrial complex II subunits SDHD, SDHB and SDHC in paraganglioma and phaeochromocytoma susceptibility , 2003, Clinical endocrinology.
[18] J. Strauchen. Germ-line mutations in nonsyndromic pheochromocytoma. , 2002, The New England journal of medicine.
[19] E S Husebye,et al. Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. , 2001, American journal of human genetics.
[20] S. L. Chew. Paraganglioma genes , 2001, Clinical endocrinology.
[21] P. Ratcliffe,et al. Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease. , 2001, Human molecular genetics.
[22] H. Neumann,et al. The challenge of kidney lesions in von Hippel-Lindau disease. , 2001, Contributions to nephrology.
[23] B. Terris,et al. [Pancreatic lesions in von Hippel-Lindau disease]. , 2000, Annales de pathologie.
[24] P. Choyke,et al. Clinical and genetic characterization of pheochromocytoma in von Hippel-Lindau families: comparison with sporadic pheochromocytoma gives insight into natural history of pheochromocytoma. , 1999, The Journal of urology.
[25] C. Wykoff,et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis , 1999, Nature.
[26] P. Choyke,et al. von Hippel-Lindau disease: genetic, clinical, and imaging features. , 1995, Radiology.
[27] H. Neumann,et al. Pheochromocytomas, multiple endocrine neoplasia type 2, and von Hippel-Lindau disease. , 1993, The New England journal of medicine.
[28] J. Gnarra,et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. , 1993, Science.
[29] M. Ferguson-Smith,et al. Clinical features and natural history of von Hippel-Lindau disease. , 1990, The Quarterly journal of medicine.
[30] K. Melmon,et al. Lindau's disease: Review of the literature and study of a large kindred , 1964 .